Past, present and future of RSV and PIV vaccines and anti-RSV antibodies for the protection of humans against RSV

Bibliography

• BECKER Y: Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy – a review. Virus Genes (2006) 33:235-252.
   PubMed Web of Science ®Google Scholar
• BECKER Y: Respiratory syncytial virus (RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment. Virus Genes (2006) 33:253-264.
   PubMedGoogle Scholar
• HALL CB: Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. (2001) 344:1917-1928.
   PubMed Web of Science ®Google Scholar
• HAN LL, ALEXANDER JP, ANDERSON LJ: Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. (1999) 179:25-30.
   PubMed Web of Science ®Google Scholar
• FALSEY AR, WALSH EE: Viral pneumonia in older adults. Clin. Infect. Dis. (2006) 42:518-524.
   PubMed Web of Science ®Google Scholar
• JOHNSON JE, GONZALEZ RA, OLSON SJ, WRIGHT PF, GRAHAM BS: The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol. (2007) 20:108-119.
   PubMed Web of Science ®Google Scholar
• GROOTHIUS JR, SIMOES EA, LEVIN MJ et al.: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. (1993) 329:1524-1530.
   PubMedGoogle Scholar
• AAP COMMITTEE ON INFECTIOUS DISEASES AND COMMITTEE OF FETUS AND NEWBORN: Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics (1998) 102(5):1211-1216.
   PubMedGoogle Scholar
• SCHENERMAN MA, HOPE JN, KLETKE C et al.: Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing. Biologicals (1999) 27:203-215.
   PubMed Web of Science ®Google Scholar
• THE IMPACT-RSV STUDY GROUP: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics (1998) 102:531-537.
   Google Scholar
• WU H, PFARR DS, TANG Y et al.: Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on virus neutralization. J. Mol. Biol. (2005) 350:126-144.
   PubMed Web of Science ®Google Scholar
• BEELER JA, VAN WYKE COELINGH K: Neutralization epitopes of F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. (1989) 63:2941-2950.
   PubMed Web of Science ®Google Scholar
• KIM HW, CANCHOLA JG, BRANDT CD et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. (1969) 89:422-434.
   PubMed Web of Science ®Google Scholar
• KAPIKIAN AZ, MITCHELL RH, CHANOCK RM, SHVEDOFF RA, STEWART CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. (1969) 89:405-421.
   PubMed Web of Science ®Google Scholar
• KAHN JS, ROBERTS A, WEIBEL C, BUONOCORE L, ROSE JK: Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. (2001) 75:11079-11087.
   PubMed Web of Science ®Google Scholar
• HALLER AA, MITIKU M, MACPHAIL M: Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. J. Gen. Virol. (2003) 84:2153-2162.
   PubMed Web of Science ®Google Scholar
• HAYNES LM, JONES LP, BARSKEY A, ANDERSON LJ, TRIPP RA: Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. (2003) 77:9831-9844.
   PubMed Web of Science ®Google Scholar
• BARTHOLDY C, OLSZEWSKA W, STRYHN A, THOMSEN AR, OPENSHAW PJ: Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. J. Gen. Virol. (2004) 85:3017-3026.
   PubMed Web of Science ®Google Scholar
• JOHNSON TR, VARGA SM, BRACIALE TJ, GRAHAM BS: Vβ14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol. (2004) 78:8753-8760.
   PubMed Web of Science ®Google Scholar
• BECKER Y: Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity. Virus Genes (2003) 27(3):269-282.
   PubMedGoogle Scholar
• TAKIMOTO T, HURWITZ JL, COLECLOUGH C et al.: Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J. Virol. (2004) 78:6043-6047.
   PubMed Web of Science ®Google Scholar
• HURWITZ JL, SOIKE KF, SANGSTER MY et al.: Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine (1997) 15:533-540.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-SOBRIDO L, GITIBAN N, FERNANDEZ-SESMA A et al.: Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. (2006) 80:1130-1139.
   PubMed Web of Science ®Google Scholar
• COLLINS PL, MURPHY BR: Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology (2002) 296:204-211.
   PubMed Web of Science ®Google Scholar
• DUDAS RA, KARRON RA: Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. (1998) 11(3):430-439.
   PubMed Web of Science ®Google Scholar
• KARRON RA, BUONAGURIO DA, GEORGIU AF et al.: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA (1997) 94:13961-13966.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD SS, BUKREYEV A, TENG MN et al.: Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. (1999) 73:3438-3442.
   PubMed Web of Science ®Google Scholar
• JIN H, ZHOU H, CHENG X, TANG R, MUNOZ M, NGUYEN N: Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH and M2-2 are attenuated in vitro and in vivo. Virology (2000) 273:210-218.
   PubMed Web of Science ®Google Scholar
• TENG MN, WHITEHEAD SS, BERMINGHAM A et al.: Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol. (2000) 74:9317-9321.
   PubMed Web of Science ®Google Scholar
• SCHMIDT AC, WENZKE DR, MCAULIFFE JM et al.: Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J. Virol. (2002) 76:1089-1099.
   PubMed Web of Science ®Google Scholar
• TANG RS, MACPHAIL M, SCHICKLI JH et al.: Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J. Virol. (2004) 78:11198-11207.
   PubMed Web of Science ®Google Scholar
• YUSIBOV V, METT V, METT V et al.: Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine (2005) 23:2261-2265.
   PubMed Web of Science ®Google Scholar
• FALSEY AR, WALSH EE: Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine (1996) 14:1214-1218.
   PubMed Web of Science ®Google Scholar
• GONZALEZ IM, KARRON RA, EICHELBERGER M et al.: Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine (2000) 18:1763-1772.
   PubMed Web of Science ®Google Scholar
• HARCOURT JL, KARRON RA, TRIPP RA: Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J. Infect. Dis. (2004) 190:1936-1940.
   PubMed Web of Science ®Google Scholar
• KARRON RA, WRIGHT PF, BELSHE RB et al.: Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. (2005) 191:1093-1104.
   PubMed Web of Science ®Google Scholar
• WRIGHT PF, KARRON RA, BELSHE RB et al.: Evaluation of a live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. (2000) 182:1331-1342.
   PubMed Web of Science ®Google Scholar
• BELSHE RB, NEWMAN FK, TSAI TF et al.: Phase II evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6 – 18 months old. J. Infect. Dis. (2004) 189:462-470.
   PubMedGoogle Scholar
• BELSHE RB, NEWMAN FK, ANDERSON EL et al.: Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J. Infect. Dis. (2004) 190:2096-2103.
   PubMed Web of Science ®Google Scholar
• SLOBOD KS, SHENEP JL, LUJAN-ZILBERMANN J et al.: Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine (2004) 22:3182-3186.
   PubMed Web of Science ®Google Scholar
• TAKIMOTO T, HURWITZ JL, ZHAN X et al.: Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol. (2005) 18:255-266.
   PubMed Web of Science ®Google Scholar
• PRINCE GA, MOND JJ, PORTER DD, YIM KC, LAN SJ, KLINMAN DM: Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. (2003) 77:13156-13160.
   PubMed Web of Science ®Google Scholar
• OUMOUNA M, MAPLETOFT JW, KARVONEN BC, BABIUK LA, VAN DRUNEN LITTEL-VAN DEN HURK S: Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J. Virol. (2005) 79:2024-2032.
   PubMed Web of Science ®Google Scholar
• MAPLETOFT JW, OUMOUNA M, TOWNSEND HG, GOMIS S, BABIUK LA, VAN DRUNEN LITTEL-VAN DEN HURK S: Formulation with CpG oligonucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology (2006) 353:316-323.
   PubMedGoogle Scholar
• BOUKHVALOVA MS, PRINCE GA, SOROUSH L, HARRIGAN DC, VOGEL SN, BLANCO JC: The TLR-4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus-enhanced disease. Vaccine (2006) 24:5027-5035.
   PubMed Web of Science ®Google Scholar
• CLUFF CW, BALDRIDGE JR, STÖVER AG et al.: Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immunol. (2005) 73:3044-3052.
   PubMed Web of Science ®Google Scholar
• MASIHI KN, LANGE W, BREHMER W, RIBI E: Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int. J. Immunopharmacol. (1986) 8:339-345.
   PubMed Web of Science ®Google Scholar
• EVANS JT, CLUFF CW, JOHNSON DA, LACY MJ, PERSING DH, BALDRIDGE JR: Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines (2003) 2:219-229.
   PubMedGoogle Scholar